Cargando…
Epoprostenol discontinuation in patients with pulmonary arterial hypertension: a complex medical and social problem
Autores principales: | Chebib, Nader, Cottin, Vincent, Taharo-Ag-Ralissoum, Martine, Chuzeville, Michel, Mornex, Jean-François |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6022074/ https://www.ncbi.nlm.nih.gov/pubmed/29283031 http://dx.doi.org/10.1177/2045893217753352 |
Ejemplares similares
-
Pulmonary hypertension in chronic lung diseases: comparison to other pulmonary hypertension groups
por: Chebib, Nader, et al.
Publicado: (2018) -
Epoprostenol sodium for treatment of pulmonary arterial hypertension
por: Saito, Yukihiro, et al.
Publicado: (2015) -
Use of Epoprostenol in the Treatment of Pulmonary Arterial Hypertension
por: Mohammadi, Asma, et al.
Publicado: (2021) -
Epoprostenol‐associated ascites in pulmonary arterial hypertension
por: Schoenberg, Noah C., et al.
Publicado: (2022) -
Impact of comorbidities and delay in diagnosis in elderly patients with pulmonary hypertension
por: Ginoux, Marylise, et al.
Publicado: (2018)